Measuring the severity of Clostridium difficile infection: implications for management and drug development

作者：Belmares Jaime^*; Gerding Dale N; Tillotson Glenn; Johnson Stuart

来源：Expert Review of Anti-Infective Therapy, 2008, 6(6): 897-908.

DOI：10.1586/14787210.6.6.897

• Clostridium difficile infection
• metronidazole
• severity of disease
• vancomycin

The appropriate management of Clostridum difficile, infection (CDI) has become a growing clinical and economic issue, as a new epidemic strain with enhanced virulence is causing increased morbidity and mortality. Presently, only two antibiotics (metronidazole and vancomycin) are routinely used to treat CDI. Both increasing disease severity and recurrent infections have been an impetus not only to develop new agents, but also to better recognize which patients are at highest risk for treatment failure and/or recurrence so that treatments can be optimized from the outset. The availability of a standardized and validated system for stratifying CDI severity could improve patient management and potentially accelerate the development of new treatment agents.

• 出版日期2008-12